autoimmune disorders — Initial data
H2 2026
The Company anticipates sharing preclinical proof-of-concept data for its therapeutic approach in the second half of 2026.Source filing
TCRX biotech catalysts & pipeline
TSCAN THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
TSC-101 — Clinical data readout
Q4 2026
The Company remains committed to reporting updated data on Cohort C patients in Q4 2026 and on all patients treated with the commercial-ready manufacturing process in Q2 2027 and intends to pursue strategic partnerships for its heme and autoimmune programs.Source filing
TSC-102-A01 and TSC-102-A03 — Initial data
2027
Initiate Phase 1 study of TSC-102-A01 and TSC-102-A03 in the fourth quarter of 2026 with initial data in 2027.Source filing
TSC-101 — Clinical data readout
Q2 2027
The Company remains committed to reporting updated data on Cohort C patients in Q4 2026 and on all patients treated with the commercial-ready manufacturing process in Q2 2027 and intends to pursue strategic partnerships for its heme and autoimmune programs.Source filing
first in vivo-engineered TCR-T product candidate — IND submission
Q3 2027
The Company expects to share preclinical data in Q1 2027 and file its first IND in Q3 2027, with plans to initiate Phase 1 development in Q4 2027.Source filing
solid tumor — IND submission
H2 2027
Established a roadmap for filing an investigational new drug (IND) application by H2 2027 after recent INTERACT engagement with the U.S. Food and Drug Administration (FDA).Source filing
TSC-101 — Topline data
mid-2028
The Company anticipates completion of enrollment and reporting of topline data from this pivotal study mid-2028.Source filing